Guardant Health
Open
$130.82
Prev. Close
$130.87
High
$131.66
Low
$130.82
Market Snapshot
$17.26B
-39.9
-3.56
$739.02M
Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 2,490 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Eventide Asset Management has significantly reduced its stake in Guardant Health, currently holding 2.5 million shares valued at approximately $256.4 million.
Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 2,490 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Recently from Cashu
Guardant Health to Showcase Innovations at Upcoming Investor Conferences in Early 2024
Guardant Health Prepares for Engaging Investor Conferences Guardant Health, Inc., a leading precision oncology company headquartered in Palo Alto, California, is set to showcase its advancements and i…
Guardant Health Engages Investors at Upcoming 2024 Conferences on Precision Oncology Innovations
Guardant Health Engages Stakeholders Through Upcoming Conferences Guardant Health, Inc., a leading precision oncology company based in Palo Alto, California, actively engages with stakeholders through…
Guardant Health Restructures Debt with New Convertible Notes for Financial Flexibility
Guardant Health's Strategic Financial Restructuring: A Focus on Convertible Notes Guardant Health, Inc., a leader in precision oncology based in Palo Alto, recently announces a significant financial r…
Guardant Health Partners with Abu Dhabi for Innovative Colorectal Cancer Screening Program
Guardant Health Partners with Abu Dhabi to Enhance Colorectal Cancer Screening Guardant Health, Inc., a leader in precision oncology, forges a significant partnership with the Abu Dhabi Public Health…